30806-86-1

Basic information

• Product Name: Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS)
• Synonyms: Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS);Methanone,(2,4-diaMino-5-pyriMidinyl)(3,4,5-triMethoxyphenyl)-;(2,4-Diamino-5-pyrimidinyl)(3,4,5-trimethoxyphenyl)methanone;Trimethoprim EP Impurity B
• CAS NO: 30806-86-1
• Molecular Formula: C₁₄H₁₆N₄O₄
• Molecular Weight: 304.30124
• Mol File: 30806-86-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS)(CAS DataBase Reference)
• NIST Chemistry Reference: Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS)(30806-86-1)
• EPA Substance Registry System: Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS)(30806-86-1)

Safety Data

• Hazardous Substances Data: 30806-86-1(Hazardous Substances Data)

Usage

Description

Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS) is a derivative of Trimethoprim, an established antibacterial agent. Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS) is characterized by its potent and selective inhibitory activity against dihydrofolate reductase, an enzyme crucial for bacterial and parasitic growth. Its molecular structure, featuring a trimethoxyphenyl group and a 2,4-diaminopyrimidin-5-yl moiety, endows it with specific properties that make it a promising candidate for various applications in the pharmaceutical and medical fields.

Uses

Used in Pharmaceutical Industry:
Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS) is used as an active pharmaceutical ingredient for the development of new drugs targeting bacterial and parasitic infections. Its potent and selective inhibition of dihydrofolate reductase makes it a valuable asset in the fight against antibiotic-resistant strains and parasitic diseases.
Used in Antimicrobial Applications:
In the field of antimicrobial research, Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS) is employed as a potent and selective inhibitor of dihydrofolate reductase, which is essential for the biosynthesis of nucleic acids and amino acids in bacteria and parasites. Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS) can be utilized to develop new treatments for bacterial and parasitic infections, particularly those that are resistant to conventional antibiotics.
Used in Treatment of Cryptosporidiosis:
Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS) is used as a therapeutic agent for the treatment of Cryptosporidiosis, a parasitic disease caused by Cryptosporidium hominis. Trimethoprim Related Compound B (25 mg) (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) (AS)'s ability to inhibit the dihydrofolate reductase of C. hominis makes it a potential candidate for developing new treatments to combat this infection, which can be particularly challenging to treat in immunocompromised individuals.

Upstream product

• 738-70-5 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine 

Downstream Products

• 56932-47-9 1-(2,4-diamino-pyrimidin-5-yl)-1-(3,4,5-trimethoxy-phenyl)-propan-1-ol 
• 920017-90-9 1-(2,4-diamino-pyrimidin-5-yl)-2-methyl-1-(3,4,5-trimethoxy-phenyl)-propan-1-ol 
• 77476-72-3 1-(2,4-diamino-pyrimidin-5-yl)-1-(3,4,5-trimethoxy-phenyl)-ethanol 
• 908343-26-0 5-[2-methyl-1-(3,4,5-trimethoxy-phenyl)-propenyl]-pyrimidine-2,4-diamine 
• 184006-38-0 5-[1-(3,4,5-trimethoxy-phenyl)-propenyl]-pyrimidine-2,4-diamine 
• 56932-55-9 5-[1-(3,4,5-trimethoxy-phenyl)-propyl]-pyrimidine-2,4-diamine 
• 184006-40-4 5-[1-(3,4,5-trimethoxy-phenyl)-vinyl]-pyrimidine-2,4-diamine 
• 77476-71-2 5-[1-(3,4,5-trimethoxy-phenyl)-ethyl]-pyrimidine-2,4-diamine 

Relevant articles and documents

Degradation of trimethoprim

Trimethoprim undergoes thermally and photochemically catalyzed hydrolysis or oxidation to give rise to at least five products. The structures of these compounds were determined by physical methods and it was found that the resonance of C-5 in the 13C NMR spectrum is indicative of the substitution pattern of the resultant amino hydroxy pyrimidines.

Studies in the effect of light on trimethoprim, furosemide and metoclopramide

Photolysis of trimethoprim, furosemide and metoclopramide under 60 W and 200 W tungsten lamp and 125 W and 250 W mercury vapour lamp in different conditions like different pH (acidic, neutral, alkaline) and different phases (solid and liquid) gave different products. Structures of these products have been established by spectral and elemental analysis.

Novel pyrimidine derivatives for drug design

TRIMETHOPRIM [2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine] (1 a) reacted with benzaldehyde and acetic anhydride to afford 2,4-disubstituted amino derivatives (1b-c). The methylene group of compounds (1a-c) was oxidized by convenient and simple method using sodium dichromate and acetic acid to give the corresponding ketonic derivatives (2a-c). (2a) was converted to the corresponding thio derivative using phosphrous pentasulphide or Lawsson's reagent which is the target of our work. The reaction of ketonic derivatives (2a-c) with different nitrogen nucleophiles have been also reported.